This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioDelivery Sciences To Host Buprenorphine Investor And Analyst Event

RALEIGH, N.C., Feb. 27, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced that the Company will host " Treatment of Pain and Opioid Dependence with Buprenorphine" for investors and analysts on Thursday, March 7, 2013 at 12:00 pm, in New York City.  This event will include insightful discussion from medical experts with extensive experience in the management of chronic pain and opioid dependence using various formulations of buprenorphine, including BDSI's BEMA Buprenorphine and BEMA Buprenorphine/Naloxone (BNX).

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO )

The presentations from physician experts include:

  • "Treatment of Chronic Pain with Buprenorphine" by Joseph Pergolizzi, M.D. Adjunct Assistant Professor at Johns Hopkins University School of Medicine and a senior partner in the Naples Anesthesia and Pain Associates Group.  He is also the co-founder and chairman for the Association of Chronic Pain Patients.
  • " Treatment of Opioid Dependence with Buprenorphine" by Gregory Sullivan, M.D. Board certified in Addiction Medicine and Medical Director of Parkway Medical Center in Birmingham, Alabama. For twenty years, Dr. Sullivan has been actively involved in government and pharmaceutical research on the mechanism, biology and treatment of addiction and pain.
  • Panel discussion featuring Genie Bailey, MD, who will address topics including patient perspectives on the treatment of opioid dependence.  Dr. Bailey is Assistant Clinical Professor of Psychiatry and Human Behavior at The Warren Alpert Medical School of Brown University and Director of Research and Medical Director of the Dual Diagnosis Unit at Stanley Street Treatment and Resources, Inc (SSTAR). 

All three experts will be on the panel and have participated in either the BEMA Buprenorphine chronic pain or BNX opioid addiction programs and will be able to offer their perspectives based on "hands on" experiences.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs